(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16%.
Upstream Bio's earnings in 2025 is -$110,059,000.On average, 5 Wall Street analysts forecast UPB's earnings for 2025 to be -$152,240,222, with the lowest UPB earnings forecast at -$160,110,998, and the highest UPB earnings forecast at -$140,164,510. On average, 5 Wall Street analysts forecast UPB's earnings for 2026 to be -$176,499,464, with the lowest UPB earnings forecast at -$246,366,081, and the highest UPB earnings forecast at -$143,938,170.
In 2027, UPB is forecast to generate -$204,586,275 in earnings, with the lowest earnings forecast at -$380,061,460 and the highest earnings forecast at -$127,226,248.